Search
for
Sort by
Research 61–90 of 1000+
- Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
- Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
- Topoisomerase‐Interacting Agents
- Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
- Chemotherapy and Cutaneous Drug Reactions
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Chemotherapy and the Skin: Understanding Dermatologic Side Effects
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Comparative Outcomes of Cutaneous Vesicostomy Versus Cystoscopic Valve Ablation in the Initial Management of Posterior Urethral Valves
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- DERMATOLOGICAL ADVERSE EFFECTS OF CHEMOTHERAPEUTIC AGENTS: EXPERIENCE FROM A TERTIARY CENTRE
- Hair casts
- Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
- [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
- Automated Machine Learning Analysis of Patients With Chronic Skin Disease Using a Medical Smartphone App: Retrospective Study
- Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses
- Successful treatment of palmoplantar pustular psoriasis with brodalumab
- Surveillance dan Penyebaran Penyakit Tangan, Kaki, dan Mulut (HFMD)
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- 3. Pediatric Dermatology
- Gender-specific side effects of chemotherapy in pancreatic cancer patients
- A skin organoid-based infection platform identifies an inhibitor specific for HFMD
- 567 Acute generalized exanthematous pustulosis (AGEP) induced by plaquenil